A Phase II Trial of Paclitaxel, 5-fluorouracil (5-FU) and Cisplatin in Patients with Metastatic or Recurrent Gastric Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We wanted to assess the effectiveness and safety of combination chemotherapy with paclitaxel, 5-fluorouracil (5-FU) and cisplatin for treating advanced gastric cancer. Materials and Methods: Patients with metastatic or recurrent gastric cancer were entered into this study. Paclitaxel at a dose of 135 mg/m² on day 1, 5-FU 1 g/m²/ day in a 24 hour continuous infusion from day 1 to day 4 and cisplatin 60 mg/m² on day 1 were administered. This regimen was repeated every 3 weeks. Results: A total of 34 patients were enrolled in this study. Among them, 33 patients were finally evaluable for their response. 17 (51.5%) patients had a partial response (95% CI: 26.0∼77.0%). The median duration of overall survival was 13.2 months. Grade 3 or 4 neutropenia and thrombocytopenia were observed in 15.2% and 1.1% of all the cycles, respectively. Grade 3 stomatitis and neurotoxicity were observed in 20.6% and 1.1% of all patients, respectively. Grade 4 non-hematologic toxicity was not observed. Conclusions: The regimen of paclitaxel, 5-FU and cisplatin demonstrated activity and accepatable toxicity for treating metastatic gastric cancer.
Abstract
Purpose: We wanted to assess the effectiveness and safety of combination chemotherapy with paclitaxel, 5-fluorouracil (5-FU) and cisplatin for treating advanced gastric cancer. Materials and Methods: Patients with metastatic or recurrent gastric cancer were entered into this study. Paclitaxel at a dose of 135 mg/m² on day 1, 5-FU 1 g/m²/ day in a 24 hour continuous infusion from day 1 to day 4 and cisplatin 60 mg/m² on day 1 were administered. This regimen was repeated every 3 weeks. Results: A total of 34 patients were enrolled in this study. Among them, 33 patients were finally evaluable for their response. 17 (51.5%) patients had a partial response (95% CI: 26.0∼77.0%). The median duration of overall survival was 13.2 months. Grade 3 or 4 neutropenia and thrombocytopenia were observed in 15.2% and 1.1% of all the cycles, respectively. Grade 3 stomatitis and neurotoxicity were observed in 20.6% and 1.1% of all patients, respectively. Grade 4 non-hematologic toxicity was not observed. Conclusions: The regimen of paclitaxel, 5-FU and cisplatin demonstrated activity and accepatable toxicity for treating metastatic gastric cancer.
참고문헌 (20)
- Edwards BK, "Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment", J Natl Cancer Inst, 97, pp.1407~27 (2005)
- 신명희, "서울시 암 발생률의 10년간 추이: 1993-2002", 예방의학회지, 41(2), pp.92~99 (2008), 대한예방의학회
- Brennan MF, "Current status of surgery for gastric cancer: a review", Gastric Cancer, 8, pp.64~70 (2005)
- Glimelius B., "Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer", Ann Oncol, 8, pp.163~8 (1997)
- Pyrhonen S., "Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer", Br J Cancer, 71, pp.587~91 (1995)
- Ohtsu A., "Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer", J Clin Oncol, 21, pp.54~9 (2003)
- Kim NK, "A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5- fluorouracil alone in the treatment of advanced gastric cancer", Cancer, 71, pp.3813~8 (1993)
- Sulkes A., "Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group", Br J Cancer, 70, pp.380~3 (1994)
- Ridwelski K., "Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer", Ann Oncol, 12, pp.47~51 (2001)
- Roth AD, "Docetaxel-based chemotherapy in the treatment of gastric cancer", Ann Oncol, 14, pp.41~4 (2003)
- Ajani JA, "Phase II study of taxol in patients with advanced gastric carcinoma", Cancer J Sci Am, 4, pp.269~74 (1998)
- Ohtsu A., "An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer", Am J Clin Oncol, 21, pp.416~9 (1998)
- Cascinu S., "Phase II study of paclitaxel in pretreated advanced gastric cancer", Anticancer Drugs, 9, pp.307~10 (1998)
- Rowinsky EK, "Sequences of taxol and cisplatin: a phase I and pharmacologic study", J Clin Oncol, 9, pp.1692~703 (1991)
- Sang Joon Shin, "The Efficacy of Paclitaxel and Cisplatin Combination Chemotherapy for the Treatment of Metastatic or Recurrent Gastric Cancer: a Multicenter Phase II Study", The Korean Journal of Internal Medicine, 20(2), pp.135~140 (2005), 대한내과학회
- Van Cutsem E., "Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group", J Clin Oncol, 24, pp.4991~7 (2006)
- Ajani JA, "Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group", J Clin Oncol, 25, pp.3210~6 (2007)
- Roth AD, "Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research", J Clin Oncol, 25, pp.3217~23 (2007)
- Kim YH, "Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma", Cancer, 85, pp.295~301 (1999)
- Lee KW, "Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer", Jpn J Clin Oncol, 35, pp.720~6 (2005)